Ampersand Capital Partners completed the acquisition of Purna Pharmaceuticals.

Ampersand Capital Partners, a middle market private equity firm, completed the acquisition of Purna Pharmaceuticals, a provider of pharmaceutical development and manufacturing services. Financial terms were not disclosed. “This acquisition marks an important next chapter for Purna and reflects Ampersand’s confidence in our leadership team, differentiated capabilities, and customer relationships. With Ampersand’s support, we are well positioned to continue investing in innovation, quality and capacity to better serve our global pharmaceutical customer base,” Bart Peeters, Purna CEO.